ERBB2 and breast cancer: Triple negative breast cancers (TNBCs) are defined through their lack of these receptors and are more difficult to manage clinically owing to the lack of protein targets, in contrast to tumors with hormone receptor or HER2 positive breast cancer, which are conventionally targeted with hormone inhibitors such as estrogen-response modulators and aromatase inhibitors or HER2-blocking antibodies, respectively [2].